Domperidone: meta-analysis of COVID-19 studies

Meta-analysis1 study · 173 patientsc19early.org

Domperidone for COVID-19

Serious outcome risk
Domperidone
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−36%
Viral clearance (1)−15%
RCTs (1)−36%
Early (1)−36%
00.511.5+
← Domperidone
reduces risk
Increased
risk →
October 2026

Domperidone COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.23
All studies−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2300.511.52+
Rotate screen for more detailsIncrease width for more details
← Domperidone
reduces risk
Domperidone
increases risk →
October 2026

Domperidone COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.23
All studies−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2300.511.52+
Rotate screen for more detailsIncrease width for more details
← Domperidone
reduces risk
Domperidone
increases risk →
October 2026

Domperidone COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment−15%1.15 · 0.73–1.8228/8724/8615% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.55
All studies−15%1.15 · 0.73–1.8228/8724/8615% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5500.511.52+
Rotate screen for more detailsIncrease width for more details
← Domperidone
reduces risk
Domperidone
increases risk →
October 2026

Domperidone COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.23
All studies−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2300.511.52+
Rotate screen for more detailsIncrease width for more details
← Domperidone
reduces risk
Domperidone
increases risk →
October 2026

Domperidone COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.23
All studies−36%1.36 · 0.83–2.2387 (n)86 (n)36% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2300.511.52+
Rotate screen for more detailsIncrease width for more details
← Domperidone
reduces risk
Domperidone
increases risk →